United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

United Therapeutics (NASDAQ:UTHR) had its price objective boosted by analysts at The Goldman Sachs Group from $243.00 to $302.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target points to a potential downside of 19.26% from the company’s previous close.

UTHR has been the subject of a number of other research reports. Argus boosted their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday. HC Wainwright boosted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday. LADENBURG THALM/SH SH boosted their target price on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. Finally, TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Price Performance

NASDAQ UTHR opened at $374.02 on Friday. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $377.92. The company has a 50-day moving average of $355.40 and a 200-day moving average of $316.65. The company has a market cap of $16.70 billion, a P/E ratio of 16.43, a P/E/G ratio of 1.35 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the prior year, the company posted $5.38 EPS. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics will post 24.85 EPS for the current year.

Insider Activity

In other news, CFO James Edgemond sold 7,782 shares of the stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the transaction, the chief financial officer now directly owns 6,426 shares in the company, valued at approximately $2,358,277.74. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $325.45, for a total transaction of $1,171,620.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $42,308.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 7,782 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the sale, the chief financial officer now directly owns 6,426 shares in the company, valued at approximately $2,358,277.74. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 98,412 shares of company stock worth $33,971,508. 11.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. ClariVest Asset Management LLC raised its position in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter valued at approximately $30,000. Innealta Capital LLC acquired a new stake in United Therapeutics in the second quarter worth $33,000. USA Financial Formulas acquired a new stake in United Therapeutics in the third quarter worth $33,000. Finally, Capital Performance Advisors LLP acquired a new stake in United Therapeutics in the third quarter worth $82,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.